Table of Contents Table of Contents
Previous Page  23 / 30 Next Page
Information
Show Menu
Previous Page 23 / 30 Next Page
Page Background

KEYNOTE016: pembrolizumab and MSI colorectal and non-

colorectal tumors

Mismatch-repair deficiency and

PD-1 blockade benefit